Merck (NYSE:MRK) announced Wednesday that a Phase 3 trial designed to test its anti-PD-1 therapy Keytruda (pembrolizumab) as ...

Merck & Co.’s stock was flat on Wednesday, after the drug company said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet the main goal of ...

An attempt by Merck & Co. to unlock the microsatellite stable (MSS) metastatic colorectal cancer market has ended in failure.

Merck follows in the footsteps of Bristol Myers Squibb, which in December 2023 also failed to secure a late-stage victory for ...

Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of ...

Recent headlines about a potent new immunotherapy have mostly focused on the U.S. company helping to develop it. Less ...

After 10 years of game-changing immunotherapies like Keytruda and Opdivo, a cancer conference celebrates — and sees more work ...

Merck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer, opening up another front in its ...

Merck is studying Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors, in a raft of trials across a wide variety of cancers and treatment settings. The company is ...

Merck & Co.’s stock fell 0.5% premarket Wednesday, after the drug company said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet the main goal ...

Folks with "high-risk" bladder cancers -- tumors that had already invaded nearby muscle -- doubled the time they were ...

For patients with newly diagnosed high-risk endometrial cancer, postsurgical Keytruda (pembrolizumab ... (inflammation of the thyroid gland), colitis (inflammation of the colon), adrenal insufficiency ...